A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours.

Udai Banerji1, Natalie Cook2, T.R. Jeffry Evans3, Irene Moreno Candilejo1, Patricia Roxburgh3, Claire L. S. Kelly2, Narmatha Sabaratnam1, Rashmi Passi1, Sawretse Leslie4, Sidath Katugampola4, Lisa Godfrey4, Neil Tremayne4, Gavin Halbert2, Gavin Bennett5, Maria Koehler6, Gillian Langford2, Marc Pittman3, Stefan N. Symeonides7

1 Institute of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton, UK; 2 University of Manchester & Christie NHS Foundation Trust, Manchester, UK; 3 University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK; 4 Cancer Research UK Centre for Drug Development, London, UK; 5 Cancer Research UK Formulary Unit, University of Strathclyde, Glasgow, UK; 6 Bicycle Therapeutics, Cambridge, UK; 7 University of Edinburgh, Edinburgh UK & Cancer Research UK Centre for Drug Development, London, UK

*email: udai.banerji@icr.ac.uk

Background - Target

MT1-MMP (MMP-14) - surface metalloproteinase involved in tissue remodelling through proteolysis of extracellular matrix components
• Highly expressed in tumours with unmet medical need, including triple negative breast cancer (TNBC) and non small cell lung cancer (NSCLC)
• Strong link with cell invasion, metastasis
• Aberrant expression correlated to poor outcomes
• High adjacent tumour stroma expression
• Low expression in adult normal tissue

BT1718 - novel first in class bicyclic targeting peptide that binds MT1-MMP and is linked to the maytansinoid tubulin inhibitor DM1 by a cleavable disulfide linker.

Open label first in human phase I/IIa study - primary objective to propose a recommended phase 2 dose (RP2D) and schedule of BT1718. Secondary objectives include pharmacokinetic (PK) parameters, and preliminary clinical responses in biomarker pre-defined cohorts of patients. Tertiary objectives include correlative blood and tissue biomarker studies.
• Accelerated dose escalation design with single patient cohorts until grade 2 drug related toxicity or target threshold, then a 3+3 design to maximum tolerated dose and RP2D
• Starting with twice a week schedule IV; will also explore once a week schedule (now open)
• Parallel expansions in MT1-MMP +ve patients, exploring clinical & biological activity, to refine schedule, biomarkers & population for final efficacy expansions

Single patient cohorts 1, 2, 3 & 4 of the twice-weekly schedule completed without significant toxicity, reaching target threshold and triggering 3+3 escalation. Cohort 5 (9.6 mg/m²) has now completed with 2x DLTs (GGT, fatigue) and a 7.2 mg/m² cohort is now open.

The once-weekly escalation is also now open (9.6 mg/m²).

Our thanks to all the patients that have kindly participated in the trial.